| |
WT vehicle
|
WT CL-316,243
|
MKR vehicle
|
MKR CL-316,243
|
|---|
| |
Baseline
|
2 weeks
|
Baseline
|
2 weeks
|
Baseline
|
2 weeks
|
Baseline
|
2 weeks
|
|---|
|
Body weight (g)
|
27.95 (0.93)
|
28.47 (1.13)
|
28.03 (0.48)
|
27.15 (0.55)
|
23.97 (1.07)a
|
24.19 (0.63)
|
22.15 (0.59)
|
22.16 (0.23)
|
|
Blood glucose (mg/dL)
|
146.43 (2.89)
|
157.29 (6.71)
|
152.75 (5.55)
|
184.88 (10.28)
|
387.60 (52.33)a
|
380.80 (24.37)
|
335.40 (36.10)
|
226.20 (16.23)b
|
|
Body fat (%)
|
14.02 (1.26)
|
12.83 (1.36)
|
12.58 (0.92)
|
6.41 (0.51)c
|
11.28 (0.71)
|
11.00 (1.07)
|
12.45 (0.77)
|
4.46 (0.40)b
|
|
Serum TG (mmol/L)
| |
2.29 (0.06)
| |
1.62 (0.03)d
| |
4.90 (0.10)e
| |
3.77 (0.04)f
|
|
Plasma insulin (ng/ml)
| |
1.50 (0.97)
| |
0.82 (0.51)
| |
8.58 (3.85)e
| |
0.80 (0.28)f
|
- Metabolic parameters from wild type (WT) and MKR mice at baseline and after 2 weeks of treatment with CL-316,243. Data in table are means of each group and SEM in parenthesis. One Way ANOVA analysis and Tukey-Kramer post-hoc significance test was performed, assuming a significance level of 5%. The following differences in the group means were found: aMKR Vehicle Baseline vs WT Vehicle Baseline; bMKR CL-316,243 2 weeks vs MKR CL-316,243 Baseline; cWT CL-316,243 2 weeks vs WT CL-316,243 Baseline; dWT CL-316,243 2 weeks vs WT Vehicle 2 weeks; eMKR Vehicle 2 weeks vs WT Vehicle 2 weeks; fMKR CL-316,243 2 weeks vs MKR Vehicle 2 weeks.
